company background image
NN6

NanoRepro XTRA:NN6 Stock Report

Last Price

€3.71

Market Cap

€47.7m

7D

7.2%

1Y

-35.0%

Updated

01 Jul, 2022

Data

Company Financials
NN6 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends4/6

NN6 Stock Overview

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally.

NanoRepro Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NanoRepro
Historical stock prices
Current Share Price€3.71
52 Week High€11.50
52 Week Low€3.25
Beta-3.93
1 Month Change4.95%
3 Month Change-20.56%
1 Year Change-35.03%
3 Year Change231.25%
5 Year Change110.80%
Change since IPO-69.59%

Recent News & Updates

Shareholder Returns

NN6DE Medical EquipmentDE Market
7D7.2%6.4%-1.1%
1Y-35.0%-15.7%-23.8%

Return vs Industry: NN6 underperformed the German Medical Equipment industry which returned -15.7% over the past year.

Return vs Market: NN6 underperformed the German Market which returned -23.8% over the past year.

Price Volatility

Is NN6's price volatile compared to industry and market?
NN6 volatility
NN6 Average Weekly Movement6.3%
Medical Equipment Industry Average Movement6.3%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.8%

Stable Share Price: NN6 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: NN6's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a19Lisa Jungsthttps://www.nanorepro.com

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test.

NanoRepro Fundamentals Summary

How do NanoRepro's earnings and revenue compare to its market cap?
NN6 fundamental statistics
Market Cap€47.74m
Earnings (TTM)€29.72m
Revenue (TTM)€162.72m

1.6x

P/E Ratio

0.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NN6 income statement (TTM)
Revenue€162.72m
Cost of Revenue€106.15m
Gross Profit€56.58m
Other Expenses€26.85m
Earnings€29.72m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.30
Gross Margin34.77%
Net Profit Margin18.27%
Debt/Equity Ratio0.3%

How did NN6 perform over the long term?

See historical performance and comparison

Dividends

13.5%

Current Dividend Yield

22%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is NN6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NN6?

Other financial metrics that can be useful for relative valuation.

NN6 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.1x
Enterprise Value/EBITDA0.5x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does NN6's PE Ratio compare to its peers?

NN6 PE Ratio vs Peers
The above table shows the PE ratio for NN6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average83.1x
MF6 MagForce
n/a149.0%€54.9m
GME Geratherm Medical
272.4xn/a€39.1m
PUS PULSION Medical Systems
27.5xn/a€157.5m
DRW3 Drägerwerk KGaA
37.6x43.5%€856.3m
NN6 NanoRepro
1.6xn/a€47.7m

Price-To-Earnings vs Peers: NN6 is good value based on its Price-To-Earnings Ratio (1.6x) compared to the peer average (83.1x).


Price to Earnings Ratio vs Industry

How does NN6's PE Ratio compare vs other companies in the European Medical Equipment Industry?

Price-To-Earnings vs Industry: NN6 is good value based on its Price-To-Earnings Ratio (1.6x) compared to the German Medical Equipment industry average (27.7x)


Price to Earnings Ratio vs Fair Ratio

What is NN6's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NN6 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio1.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NN6's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NN6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NN6 (€3.71) is trading below our estimate of fair value (€169.61)

Significantly Below Fair Value: NN6 is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NN6's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is NanoRepro forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.6%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoRepro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether NanoRepro is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • NanoRepro competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has NanoRepro performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


89.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NN6 has a high level of non-cash earnings.

Growing Profit Margin: NN6's current net profit margins (18.3%) are higher than last year (10%).


Past Earnings Growth Analysis

Earnings Trend: NN6 has become profitable over the past 5 years, growing earnings by 89% per year.

Accelerating Growth: NN6's earnings growth over the past year (1653.6%) exceeds its 5-year average (89% per year).

Earnings vs Industry: NN6 earnings growth over the past year (1653.6%) exceeded the Medical Equipment industry 1.3%.


Return on Equity

High ROE: NN6's Return on Equity (51.6%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is NanoRepro's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: NN6's short term assets (€79.0M) exceed its short term liabilities (€11.0M).

Long Term Liabilities: NN6's short term assets (€79.0M) exceed its long term liabilities (€10.5M).


Debt to Equity History and Analysis

Debt Level: NN6 has more cash than its total debt.

Reducing Debt: NN6's debt to equity ratio has reduced from 5.1% to 0.3% over the past 5 years.

Debt Coverage: NN6's debt is well covered by operating cash flow (5476.2%).

Interest Coverage: NN6's interest payments on its debt are well covered by EBIT (741.3x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is NanoRepro current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


13.48%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: NN6's dividend (13.48%) is higher than the bottom 25% of dividend payers in the German market (1.5%).

High Dividend: NN6's dividend (13.48%) is in the top 25% of dividend payers in the German market (4.49%)


Stability and Growth of Payments

Stable Dividend: Too early to tell whether NN6's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if NN6's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (21.7%), NN6's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: At its current cash payout ratio (78.6%), NN6's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Lisa Jungst

9.17yrs

Tenure

Ms. Lisa Jüngst serves as President of the Management Board at NanoRepro AG and has been its Member of Management Board since April 2013. She is Chief Executive Officer at NanoRepro AG. Ms. Jüngst served...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.3%.


Top Shareholders

Company Information

NanoRepro AG's employee growth, exchange listings and data sources


Key Information

  • Name: NanoRepro AG
  • Ticker: NN6
  • Exchange: XTRA
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €47.744m
  • Shares outstanding: 12.90m
  • Website: https://www.nanorepro.com

Number of Employees


Location

  • NanoRepro AG
  • Untergasse 8
  • Marburg
  • Hessen
  • 35037
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/01 00:00
End of Day Share Price2022/07/01 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.